Quest Laboratories Ltd (QUESTLAB) — shareholding pattern, promoter holding, financials and share price
About Quest Laboratories Ltd (QUESTLAB)
Quest Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as QUESTLAB and on the BSE under scrip code 92906. Its ISIN is INE0TNW01017.
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments [1]
Quest Laboratories Limited specializes in the manufacturing of a wide range of pharmaceutical formulations, including ethical and generic drugs.
The company is experiencing rapid growth, evidenced by a 52% year-over-year increase in Q1FY26 revenues, thanks to expanded operations and product lines.
Listed peers in Pharmaceuticals: Panchsheel Organics Ltd, Auro Laboratories Ltd, Natural Capsules Ltd, Kimia Biosciences Ltd, Alpa Laboratories Ltd, Smruthi Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹91.2 a share on 10 Jul 2026, Quest Laboratories Ltd (QUESTLAB) was valued at a price-to-earnings ratio of 9.95x against an industry P/E of 36.41x and a price-to-book of 1.83x on a book value of ₹49.92 per share as of Mar 2025. Solomo computes return on equity of 18.36% and return on capital employed of 17.8% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 9.95x
- Industry P/E
- 36.41x
- P/B
- 1.83x
- EPS (TTM)
- ₹9.17
- Book value / share
- ₹49.92
- ROE
- 18.36%
- ROCE
- 17.8%
- ROA
- 12.35%
- Debt / equity
- 0.37x
- Dividend yield
- 0%
- EBITDA margin
- 18.58%
- 52-week range
- ₹84 – ₹152.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Quest Laboratories Ltd (QUESTLAB) reported revenue of ₹112 crore, net profit of ₹15 crore and earnings per share of ₹9.17. That compares with revenue of ₹104 crore and net profit of ₹14 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹32.4 crore and net profit ₹2.87 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 59 | 62 | 83 | 104 | 112 |
| Net profit (₹ cr) | 4 | 5 | 10 | 14 | 15 |
| EPS (₹) | - | - | 8.45 | 8.28 | 9.17 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 20.46% | 25.93% |
| Profit growth | 48.95% | 34.49% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 66.78% of Quest Laboratories Ltd (QUESTLAB) (unchanged from the previous quarter). Market capitalisation was ₹149 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Mar 2026: YASHVI HITESH PATEL 3.41%, HARSHA VENKATESH 2.35%, DIMPLE KOTHARI 1.6%, Sunil Kumar Chhabra 1.08%, SANDEEP KOTHARI 1.06%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 66.78% | - | - | - | - |
| Dec 2025 | 66.78% | - | - | - | - |
| Sep 2025 | 66.78% | - | - | - | - |
| Mar 2025 | 66.21% | - | - | - | - |
| Dec 2024 | 65.83% | - | - | - | - |
| Sep 2024 | 65.83% | - | - | - | - |